

JAN 23 2003
PATENT & TRADEMARK OFFICE

SHEET 1 OF 1

Substitute for forms 1449A/PTO & 1449B/PTO

ATTORNEY'S DKT NO.
017751-021

APPLICATION NO.
09/801,751

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT
Jean-Pierre ROBIN et al




FILING DATE
March 9, 2001

GROUP
1614

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes	No
	0393575		EP	10-27-1990	X	
	00/40269		WO	07-13-2000	X	
	02/32904		WO	10-17-2000	X	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>[Signature]</i>	U.S. Statutory Invention Registration H271, published May 5, 1987.
<i>[Signature]</i>	J M Whaun et al, "Treatment of Chloroquine-Resistant Malaria with Esters of Cephalotaxine Homoharringtonine," Ann Trop Med Parasitol, Vol. 84, No. 3, 1990, pp. 229-237.
<i>[Signature]</i>	H.M. Kantarjian et al, "Chronic myelogenous leukemia - Progress at the M. D. Anderson Cancer Center over the past two decades and future directions: First Emil J. Freireich Award Lecture," Clinical Cancer Research, 1997, pp. 2723-2733.
<i>[Signature]</i>	Vincent Levy et al, "Subcutaneous homoharringtonine (SQ HHT): 1. Pharmacokinetic study in dogs and HHT determination in blood in using LC-MS method," Blood, Vol. 98, NO. 11, part 2, November 16, 2001, pp. 179B. <i>ABSTRACT ONLY</i>
<i>[Signature]</i>	Vincent Levy et al, "Subcutaneous homoharringtonine (SQ HHT): 2. Tolerance in Humans and case report of a refractory patient with AML treated by very small dose of SQ HHT," Blood, Vol. 98, No. 11, Part 2, November 16, 2001, pp. 202B. <i>ABSTRACT ONLY</i>
<i>[Signature]</i>	

Examiner Signature		Date Considered	2/10/03
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

~~*~~ no copies.